Heidelberg Pharma AG Reports Progress in Q1 2026

In the first quarter of 2026, Heidelberg Pharma AG achieved significant milestones both financially and clinically. The completion of Phase I clinical trials with HDP-101 for multiple myeloma marked a crucial step. The dose-escalation study showed promising safety and efficacy results, leading to the commencement of Phase IIa trials. Additionally, developments with partners Takeda and Huadong Medicine initiated milestone payments, enhancing financial prospects.

The company reported revenues totaling EUR 4.1 million, attributed mainly to milestone payments, marking an increase from the previous year. Operating expenses decreased slightly, with research and development as the primary cost driver.

Financial measures included a USD 20 million payment from Soleus Capital extending funding through mid-2027. The net loss reduced to EUR 4.3 million, reflecting improved earnings per share. Looking ahead, Heidelberg Pharma anticipates continued financial stability and advancement in its drug candidates.